MaxCyte inks development agreement with KSQ Therapeutics

Writer,

Archived article

Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.

Cell-based therapies group MaxCyte said it had entered into a development agreement with KSQ Therapeutics.

The pact would see KSQ gain rights to use MaxCyte's technology for the advancement of its engineered tumor-infiltrating lymphocyte programs, being developed for the treatment of refractory solid tumors.

In return, MaxCyte would be eligible to receive certain milestone payments in addition to other licensing fees.